The usefulness of intracellular adenosine-5'-triphosphate measurement in CD4+ cells in renal transplant;Utilidad de la medición de adenosina 5'-trifosfato intracelular en células CD4+ en trasplante renal

Nefrologia

Volumn 33, Issue 3, 2013, Pages 381-388

  López Hoyos, Marcos ^a   Rodrigo, Emilio ^a   Arias, Manuel ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Comorbidity; Immunosuppression; Mortality; Patient survival; Renal transplantation

Indexed keywords

ADENOSINE TRIPHOSPHATE;

ARTICLE; BIOSYNTHESIS; CD4+ T LYMPHOCYTE; CHEMISTRY; HUMAN; INTRACELLULAR MEMBRANE; KIDNEY TRANSPLANTATION; METABOLISM;

ADENOSINE TRIPHOSPHATE; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; INTRACELLULAR MEMBRANES; KIDNEY TRANSPLANTATION;

EID: 84878069913     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Oct.11540     Document Type: Article

References (44)

1. Rovira P, Mascarell L, Truffa-Bach P. The impact of immune suppressive drugs on the analysis of T cell activation. Curr Med Chem 2000;7:673-92.
2. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14.
3. Lodhi S, Lamb K, Meier-Kriesche H. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011;11:1226-35.
4. Lamb K, Lodhi S, Meier-Kriesche H. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62.
5. Wieland E, Olbricht CJ, Susal C, Gurragchaa P, Böhler T, Israeli M, et al. Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit 2010;32:560-72.
6. United States Department of Health and Human Services. K013196; Cylex Immune Cell Function Assay, April 02, 2002.
7. United States Department of Health and Human Services. K013196; Immuknow® Immune Cell Function Assay, October 18, 2010.
8. Kowalski R, Post D, Schneider M, Britz J, Thomas J, Deierhoi M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003;17:77-88.
9. Buttgereit F, Burmester G-R, Brand MD. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000;21:192-9.
10. Nankivell BJ, Alexander SI. Rejection of the Kidney Allograft. N Engl J Med 2010;363:1451-62.
11. Kowalski RJ, Zeevi A, Mannon RB, Britz JA, Carruth LM. Immunodiagnostics: Evaluation of functional T-cell immunocompetence in whole blood independent of circulating cell numbers. J Immunotoxicol 2007;4:225-32.
12. Augustine N, Pasi B, Hill H. Comparison of ATP production in whole blood and lymphocyte proliferation in response to phytohemagglutinin. J Clin Lab Anal 2007;21:265-70.
13. Serban G, Whittaker V, Fan J, Liu Z, Manga K, Khan M, et al. Significance of immune cell monitoring in renal transplantation after thymoglobulin induction therapy. Hum Immunol 2009;70:882-90.
14. Roedder S, Vitalone M, Khatri P, Sarwal M. Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. Genome Medicine 2011;3:37-49.
15. Kowalski R, Post D, Mannon RB, Sebastian A, Wright HI, Sigle G, et al. Assessing relative risks of infection and rejection: a meta-analysis using immune function assay. Transplantation 2006;82(5):663-8.
16. Cadillo-Chávez R, de Echegaray S, Santiago-Delpín EA, Rodríguez-Trinidad AT, Camacho-Carrazo B, Alfaro T, et al. Assessing the risk of infection and rejection in Hispanic renal transplant recipients by means of an adenosine triphosphate release assay. Transplant Proc 2006;38:918-20.
17. Pérez-Flores I, Sánchez-Fructuoso A, Santiago JL, Fernández-Arquero M, Calvo N, de la Concha EG, et al. Intracellular ATP levels in CD4 lymphocytes are a risk marker of rejection and infection in renal graft recipients. Transplant Proc 2009;41:2106-8.
18. Torío A, Fernández EJ, Montes-Ares O, Guerra RM, Pérez MA, Checa MD. Lack of association of immune cell function test with rejection in kidney transplantation. Transplant Proc 2011;43:2168-70.
19. De Paolis P, Favarò A, Piola A, Martini F, Cristiana G, Agrati C, et al. "ImmuKnow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant Proc 2011;43(4):1013-6.
20. Batal I, Zeevi A, Heider A, Girnita A, Basu A, Tan H, et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK reactivation. Am J Clin Pathol 2008;129:587-91.
21. Sánchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernández-Fresnedo G, López-Hoyos M, et al. Intracellular ATP concentrations of CD cells in kidney transplant patients with and without infection. Clin Transplant 2008;22:55-60.
22. Israeli M, Yussim A, Mor E, Sredni B, Klein T. Preceding the rejection: in search for a compre-hensive posttransplant immune monitoring platform. Transplant Immunol 2007;18(1):7-12.
23. Vats A, Randhawa PS, Shapiro R. Diagnosis and treatment of BK virus-associated transplant nephropathy. Adv Exp Med Biol 2006;577:213-27.
24. Randhawa P, Vats A, Shapiro R. The pathobiology of polyomavirus infection in man. Adv Exp Med Biol 2006;577:148-59.
25. Huskey J, Gralla J, Wiseman A. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011;6:423-9.
26. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005;5:582-94.
27. Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010;10:2615-23.
28. Cannon RM, Ouseph R, Jones CM, Hughes MG, Eng M, Marvin MR. BK viral disease in renal transplantation. Curr Opin Organ Transplant 2011;16:576-9.
29. Gautam A, Morrissey PE, Brem AS, Fischer SA, Gohh RY, Yango AF, et al. Use of an immune function assay to monitor immunosuppression for treatment of posttransplant lymphoproliferative disorder. Pediatr Transplant 2006;10:613-6.
30. Gautam A, Fischer SA, Yango AF, Gohh RY, Morrissey PE, Monaco AP. Cell-mediated immunity (CMI) and posttransplant viral infections. Role of a functional immune assay to titrate immunosuppression. Int Immunopharmacol 2006;6(13-14):2023-6.
31. Ling X, Xiong J, Liang W, Schroder PM, Wu L, Ju W, et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012;93:737-43.
32. Rodrigo E, López-Hoyos M, Corral M, Fábrega E, Fernández-Fresnedo G, San Segundo D, et al. ImmuKnow(®) as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: Systematic review and meta-analysis. Liver Transpl. 2012;18:1245-53.
33. Helantera I, Koskinen P. Association of immune cell function assay with protocol biopsy findings and viral infections in well matched kidney transplant recipients. Clin Nephrol 2010;74:123-31.
34. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J; FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008;8:307-16.
35. Matas AJ. Resolved: In minimizing kidney transplant immunosuppression, steroids should go before calcineurin inhibitors. J Am Soc Nephrol 2007;18:3026-30.
36. Zeng X, El-Amm JM, Doshi MD, Singh A, Morawski K, Cincotta E, et al. Intermediate-term outcomes with early steroid withdrawal in African-American renal transplant recipients undergoing surveillance biopsy. Surgery 2007;142:538-45.
37. Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, et al. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Clin Transplant 2008;22:645-50.
38. Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC, for the TRMIS Study Investigators. A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin® in living-donor kidney transplantation. Clin Transplant 2010;24:73-83.
39. Li S, Wang W, Hu Z, Ren L, Yin H, Yang X, et al. The effects of early rapid corticosteroid reduction on cell-mediated immunity in kidney transplant recipients. Transpl Immunol 2011;24:127-30.
40. Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, et al. A pilot study of immunosuppression minimization after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Transplant Proc 2005;37:3538-41.
41. San Segundo D, Fernández-Fresnedo G, Gago M, Beares I, Ruiz-Criado J, González M, et al. Number of peripheral blood regulatory T-cells and lymphocyte activation at 3 months after conversion to mTOR inhibitor therapy. Transplant Proc 2010;42:2871-3.
42. Rajab A, Pelletier RP, Henry ML, Ferguson RM. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006;20:537-46.
43. Brunet M, Campistol JM, Diekmann F, Guillen D, Millan O. T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther 2007;11(4):247-56.
44. Jørgensen PF, Wang JE, Almlöf M, Solberg R, Okkenhaug C, Scholz T, et al. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 2001;53:184-91